Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

This trial is testing whether combining two drugs — nivolumab (an immune-boosting drug) and ruxolitinib (a drug that blocks certain inflammation signals) — can help treat Hodgkin lymphoma (a blood cancer) that has come back or stopped responding to treatment. **You may be eligible if...** - You are 18 or older - You have been diagnosed with classical Hodgkin lymphoma that came back or did not respond to treatment - You have already tried at least one prior treatment, including a checkpoint inhibitor drug (like nivolumab or pembrolizumab) - Your cancer can be seen and measured on scans - Your blood counts and organ function meet minimum health thresholds - You can swallow pills **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have a serious illness or organ dysfunction that makes the treatment too risky - You have an active autoimmune disease requiring ongoing immune-suppressing treatment - You have had certain types of prior organ or stem cell transplants - You have active hepatitis B or C, or HIV - You have uncontrolled heart rhythm problems Talk to your doctor to see if this trial is right for you.